4.6 Article

First-in-man safety evaluation of renal denervation for chronic systolic heart failure: Primary outcome from REACH-Pilot study

期刊

INTERNATIONAL JOURNAL OF CARDIOLOGY
卷 162, 期 3, 页码 189-192

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.ijcard.2012.09.019

关键词

Renal denervation; Systolic heart failure; Blood pressure; Sympathetic nervous system; Sympathetic overactivation

资金

  1. British Heart Foundation [FS/11/46/28861, FS/05/006, FS/10/038]
  2. British Heart Foundation [PG/11/53/28991, FS/10/38/28268, FS/11/46/28861] Funding Source: researchfish
  3. National Institute for Health Research [NF-SI-0508-10116] Funding Source: researchfish

向作者/读者索取更多资源

Background: Sympathetic overactivation, is reduced by renal denervation in drug-resistant hypertension. A similar role for renal denervation in heart failure remains unstudied, partly due to the concern about potential concomitant deleterious blood pressure reductions. This pilot study evaluated the safety of renal denervation for heart failure using an intensive follow-up protocol. Method: 7 patients (mean age 69 years) with chronic systolic heart failure (mean BP on referral 112/65 mm Hg) on maximal tolerated heart failure therapy underwent bilateral renal denervation May-July 2011. Patients were admitted for pre-procedure baseline assessments and in-patient observation for 5 days following denervation. Follow-up was weekly for 4 weeks, and then monthly for 6 months. Results: No significant haemodynamic disturbances were noted during the acute phase post renal denervation. Over 6 months there was a non-significant trend to blood pressure reduction (Delta systolic -7.1 +/- 6.9 mm Hg, p=0.35; Delta diastolic -0.6 +/- 4.0 mm Hg, p=0.88). No hypotensive or syncopal episodes were reported. Renal function remained stable (Delta creatinine -5.7 +/- 8.4 mu mol/l, p=0.52 and Delta urea -1.0 +/- 1.0 mmol/l, p=0.33). All 7 patients described themselves as symptomatically improved. The six minute walk distance at six months was significantly increased (Delta =27.1 +/- 9.7 m, p=0.03), with each patient showing an increase. Conclusions: This study found no procedural or post procedural complications following renal denervation in patients with chronic systolic heart failure in 6 months of intensive follow-up. Results suggested improvements in both symptomsand exercise capacity, but further randomised, blinded sham-controlled clinical trials are required to determine the impact of renal denervation on morbidity and mortality in systolic heart failure. These data suggest such trials will be safe. (C) 2012 Elsevier Ireland Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据